Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE: 603079)
Health Care · Pharmaceuticals · CN
CN¥14.03
+4.62% today · -21.8% 1Y
Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE: 603079) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $391.19M and employs 1,083 people.
Over the last twelve months the share price has lost 21.8%, trading between 9.94 and 22.00.
Tweenvest scores Zhejiang Shengda Bio-Pharm Co., Ltd. across four factors: quality 74/100, value 42/100, growth 6/100, dividend 46/100. Its strongest factor is quality.
603079 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $391.19M
- Revenue (TTM)
- $120.41M
- P/E
- 47.85
- EPS
- 0.29
- Dividend yield
- 0.71%
- Beta (5Y)
- 0.30
- 52-week high
- CN¥22.00
- 52-week low
- CN¥9.94
- Avg volume (3M)
- —
- Shares outstanding
- 187.44M
- Employees
- 1,083
- Next earnings
- —
About Zhejiang Shengda Bio-Pharm Co., Ltd.
Zhejiang Shengda Bio-Pharm Co., Ltd., based in Tiantai, China, is a global enterprise dedicated to the research, development, manufacturing, and distribution of a diverse range of food and animal feed additives. The company's comprehensive product portfolio includes essential vitamins like biotin and folic acid, biological preservation agents such as nisin and natamycin, and intermediate Active Pharmaceutical Ingredients (APIs). They also provide various natural solutions for food preservation.
- ISIN
- CNE100002W43
- Founded
- 1999
- Listed since
- Aug 23, 2017
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.